Skip to content
Company Analysis

Evolus, Inc. Common Stock EOLS

A comprehensive view of key metrics, scores, and financial health for Evolus, Inc. Common Stock

Overview of Evolus, Inc.

EOLS NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Evolus, Inc. (EOLS), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $7.17, about 9.8% undervalued vs fair value, +1.8% 1Y return, ranked 610/1145 in sector.
Metrics Rev Growth 11.6% ROE 587.4% Gross Margin 66.3%
USD 7.17
2.28%
(Delayed)
• Vol 90d: 57.9%
52-Week Range
Market Cap
$473.60M
Enterprise Value
$585.17M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 89%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.evolus.com
HQ Newport Beach, CA
Employees 329
Fiscal year Dec 31

Next Events

Earnings Nov 4 Call: Nov 4

Fair Value Snapshot

Bear Base Bull
$7
$8
$9
Current: $7.17 +10% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$297.2M
11.6%%
Gross Profit
$197.1M
8.1%%
R&D Expense
$9.6M
4.4%%
Operating Income (EBIT)
-$31.3M
-0.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
3.2%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Evolus, Inc. Common Stock's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
39
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.68), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 35.4th percentile suggests inefficient capital deployment.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.34), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
42
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 80% Coverage
Trade-Off Triangle Visualization A ternary plot showing EOLS's balance between Growth (45.0%), Profitability (24.4%), and Safety (30.6%). Growth 45% Safety 31% Profitability 24%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

66th percentile vs peers
66
Key Signals
Revenue CAGR 3Y 26.0% 86p Rev Growth YoY 11.6% 71p EPS Growth YoY 1.1% 32p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (26.0%, 86th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Debt/FCF Ratio in top 20% of peers (-2.88, 92th percentile)
Risks

No significant risks identified for this axis.

Profitability

35th percentile vs peers
36
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

44th percentile vs peers
45
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Evolus, Inc. Common Stock.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$7.87
- - -
+9.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000